Abstract
BackgroundPancreatic cancer (PC) is a devastating disease that has a poor prognosis and a total 5-year survival rate of around 5%. The poor prognosis of PC is due in part to a lack of suitable biomarkers that can allow early diagnosis. The lysophospholipase autotaxin (ATX) and its product lysophosphatidic acid (LPA) play an essential role in disease progression in PC patients and are associated with increased morbidity in several types of cancer. In this study, we evaluated both the potential role of serum LPA and ATX as diagnostic markers in PC and their prognostic value for PC either alone or in combination with CA19-9.MethodsATX, LPA and CA19-9 levels were evaluated using ELISA of serum obtained from PC patients (n = 114) healthy volunteers (HVs: n = 120) and patients with benign pancreatic diseases (BPDs: n = 94).ResultsSerum levels of ATX, LPA and CA19-9 in PC patients were substantially higher than that for BPD patients or HVs (p < 0.001). The sensitivity of LPA in early phase PC was 91.74% and the specificity of ATX was 80%. The levels of ATX, LPA and CA19-9 were all substantially higher for early stage PC patients compared to levels in serum from BPD patients and HVs. The diagnostic efficacy of CA19-9 for PC was significantly enhanced by the addition of ATX and LPA (p = 0.0012).ConclusionMeasurement of LPA and ATX levels together with CA19-9 levels can be used for early detection of PC and diagnosis of PC in general.
Highlights
Pancreatic cancer (PC) is a devastating disease that has a poor prognosis and a total 5-year survival rate of around 5%
Patients Serum samples were gathered from 328 individuals, who were divided into three groups: Group A had 114 PC patients, Groups B and Group C served as cohort control groups and comprised 120 healthy volunteers (HVs) and 94 patients with benign pancreatic diseases (BPDs), respectively
Characteristics of PC and BPD patients and healthy volunteers Overall, 120 HVs, 94 patients with BPDs and 114 PC patients were enrolled in this study
Summary
Pancreatic cancer (PC) is a devastating disease that has a poor prognosis and a total 5-year survival rate of around 5%. The poor prognosis of PC is due in part to a lack of suitable biomarkers that can allow early diagnosis. The lysophospholipase autotaxin (ATX) and its product lysophosphatidic acid (LPA) play an essential role in disease progression in PC patients and are associated with increased morbidity in several types of cancer. Diagnosis and improved treatments have together contributed to increased survival rates for several types of cancer over the recent decades. In patients with resect-able tumors, the 5-year survival rate for PC ranges from 15 to 20%. For those PC patients presenting with unresectable tumors and distant metastases, the 5-year. New, more sensitive biomarkers that can be used either alone or in combination with previously defined biomarkers are needed to increase the likelihood of early PC detection [6]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
